To Evaluate the Safety, Efficacy, and Protection of Micardis 80 mg/Micardis Plus 80/12.5 mg From Cardiovascular Risks in a 24 Weeks Observational Study in Patients With Essential Hypertension Who Have at Least One Other Known Cardio-Vascular Risk Factor.
Phase of Trial: Phase IV
Latest Information Update: 29 Jun 2012
At a glance
- Drugs Telmisartan; Telmisartan/hydrochlorothiazide
- Indications Essential hypertension
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRO-POWER
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 11 Mar 2011 Actual end date (November 2010) added as reported by ClinicalTrials.gov.
- 11 Mar 2011 Status changed from recruiting to completed reported by ClinicalTrials.gov.
- 17 Aug 2010 Planned end date changed from 1 May 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.